News Ono poised to join Daiichi in TGCT market after FDA nod Ono Pharmaceutical has claimed FDA approval for Romvimza as a treatment for tenosynovial giant cell tumour (TGCT).
News Ono swoops on Deciphera in $2.4 billion takeover Japan’s Ono Pharma has bolstered its cancer pipeline with a $2.4 billion agreement to buy Deciphera Pharma of the US and its fast-growing gastrointestinal stromal tumour (
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
